ATE490787T1 - Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion - Google Patents

Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Info

Publication number
ATE490787T1
ATE490787T1 AT04747833T AT04747833T ATE490787T1 AT E490787 T1 ATE490787 T1 AT E490787T1 AT 04747833 T AT04747833 T AT 04747833T AT 04747833 T AT04747833 T AT 04747833T AT E490787 T1 ATE490787 T1 AT E490787T1
Authority
AT
Austria
Prior art keywords
igm
production
quantifying
transformed cells
chain
Prior art date
Application number
AT04747833T
Other languages
English (en)
Inventor
Reiko Irie
Hiroyuki Tsunoda
Tomoyuki Igawa
Yasuo Sekimori
Masayuki Tsuchiya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE490787T1 publication Critical patent/ATE490787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04747833T 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion ATE490787T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48733303P 2003-07-15 2003-07-15
PCT/JP2004/010444 WO2005005636A1 (ja) 2003-07-15 2004-07-15 形質転換細胞によるIｇMの産生とその定量方法

Publications (1)

Publication Number Publication Date
ATE490787T1 true ATE490787T1 (de) 2010-12-15

Family

ID=34062150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04747833T ATE490787T1 (de) 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Country Status (9)

Country Link
US (2) US7709615B2 (de)
EP (2) EP2204190A1 (de)
JP (1) JP5452835B2 (de)
AT (1) ATE490787T1 (de)
AU (1) AU2004256354B2 (de)
CA (1) CA2532966C (de)
DE (1) DE602004030451D1 (de)
TW (1) TW200510532A (de)
WO (1) WO2005005636A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
DK1835022T3 (en) 2005-01-05 2015-02-23 Chugai Pharmaceutical Co Ltd CELL CULTIVATION PROCEDURE AND UTILIZATION OF THIS
WO2007002676A2 (en) * 2005-06-27 2007-01-04 Invitrogen Corporation Liquid protein markers for native gel electrophoresis
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP1977763A4 (de) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antikörper-enthaltende stabilisierende zubereitung
ES2409844T3 (es) * 2006-01-30 2013-06-28 Grifols Therapeutics Inc. Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
BRPI0818674B1 (pt) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102164962B (zh) * 2008-06-30 2014-05-28 诺福泰克公司 抗gd2抗体和方法及其相关应用
JP5232241B2 (ja) * 2008-10-31 2013-07-10 独立行政法人科学技術振興機構 ヘルパーｔ細胞の選択的機能制御法
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
ES2655077T3 (es) * 2012-04-17 2018-02-16 Mayo Foundation For Medical Education And Research Anticuerpos humanos y secuencias de unión específicos del mismo para uso en accidente cerebrovascular e isquemia y condiciones isquémicas
CA2888652C (en) * 2012-11-30 2020-09-22 Katinger Gmbh Recombinant human igm-antibody effective against cancer cells
US20140199319A1 (en) * 2012-12-14 2014-07-17 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
EP4671270A3 (de) 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur reinigung eines antikörpers mit niedrigem isoelektrischen punkt
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3185004A4 (de) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
EP3750918A1 (de) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumornekrosefaktor-superfamilienrezeptorbindende moleküle und verwendungen davon
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) * 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
US10572893B2 (en) 2016-06-16 2020-02-25 International Business Machines Corporation Discovering and interacting with proximate automobiles
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP3805112A4 (de) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha Fülldüse
EP4003333A4 (de) * 2019-07-31 2023-11-01 The Wistar Institute for Anatomy and Biology Multivalente dna-antikörperkonstrukte und ihre verwendung
US20230212293A1 (en) * 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
EP4297786A4 (de) * 2021-02-23 2025-01-22 Pandion Operations, Inc. Pd-1-antikörper, polypeptide und verwendungen davon
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
ATE82136T1 (de) 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
US5157113A (en) 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
CA1312030C (en) 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US6238891B1 (en) 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
JP2501116B2 (ja) 1988-03-05 1996-05-29 日本電信電話株式会社 巡回制御形回線交換方法
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
GB9010944D0 (en) 1990-05-16 1990-07-04 Central Blood Lab Authority Chemical compounds
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0492409A1 (de) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Menschlicher monoklonaler Antikörper
JPH05192181A (ja) 1990-12-18 1993-08-03 Ishihara Sangyo Kaisha Ltd ヒトモノクローナル抗体
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JPH04360696A (ja) * 1991-06-06 1992-12-14 Sumitomo Chem Co Ltd 新規なヒトｂリンパ細胞株を宿主として産生された組み換えヒト抗体
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP3565572B2 (ja) 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
JPH06178689A (ja) * 1992-12-11 1994-06-28 Mitsui Toatsu Chem Inc Ｉ型緑膿菌を抗原とするヒト抗体をコードする遺伝子
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
JPH09127112A (ja) 1995-10-30 1997-05-16 Dainabotsuto Kk 修飾ＩｇＭ免疫学的測定試薬
JPH09127114A (ja) 1995-11-01 1997-05-16 Dainabotsuto Kk 免疫学的測定用安定化ＩｇＭ試薬
AU730457B2 (en) 1996-08-16 2001-03-08 President And Fellows Of Harvard College Soluble monovalent and multivalent MHC class II fusion proteins, and uses therefor
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
EP1047457A2 (de) 1998-01-16 2000-11-02 MCA Development B.V. Radiomarkierte monoklones igm zür therapie von krebs und autoimmunkrankheit
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP2002504342A (ja) * 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
JP2000154149A (ja) * 1998-09-18 2000-06-06 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体含有抗リウマチ剤
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
EP1176195B1 (de) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
AU7449200A (en) 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
EP1226752A4 (de) 1999-11-05 2004-05-06 Kyowa Hakko Kogyo Kk Transgene nicht-humane tiere zur überwachung einer veränderung der kalzium-ionenkonzentration in zellen
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US6586785B2 (en) 2000-06-29 2003-07-01 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
US20040081972A1 (en) 2000-08-01 2004-04-29 Mitsuo Satoh Novel physiologically active peptide and use thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2003128576A (ja) * 2001-10-25 2003-05-08 Taisho Pharmaceut Co Ltd エンドトキシン誘発性疾患治療薬
AU2002356749A1 (en) 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
DE10328295B4 (de) 2003-06-23 2007-11-22 Endress + Hauser Gmbh + Co. Kg Verfahren und entsprechende Vorrichtung zum Schweißen von Bauteilen eines Feldgerätes
WO2005003557A1 (en) 2003-06-25 2005-01-13 Design Net Engineering, Llc Laser propulsion thruster
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions

Also Published As

Publication number Publication date
TWI342336B (de) 2011-05-21
AU2004256354B2 (en) 2011-07-07
EP1652925A1 (de) 2006-05-03
AU2004256354A1 (en) 2005-01-20
EP1652925A4 (de) 2007-07-04
US20100172899A1 (en) 2010-07-08
WO2005005636A1 (ja) 2005-01-20
DE602004030451D1 (de) 2011-01-20
TW200510532A (en) 2005-03-16
JP5452835B2 (ja) 2014-03-26
US8257703B2 (en) 2012-09-04
CA2532966C (en) 2012-12-04
US20070154469A1 (en) 2007-07-05
EP1652925B1 (de) 2010-12-08
CA2532966A1 (en) 2005-01-20
EP2204190A1 (de) 2010-07-07
JPWO2005005636A1 (ja) 2006-08-24
US7709615B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
ATE490787T1 (de) Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
PL2314620T3 (pl) Sposób identyfikowania cząsteczek wiążących zdolnych do neutralizowania wirusa wścieklizny
EP1427445A4 (de) Verfahren zur reifung von plasmacytoiden dendritischen zellen unter verwendung von die immunantwort modifizierenden molekülen
DE60224643D1 (de) Verfahren zur herstellung von reifen
WO2004022714A3 (en) Organic species that facilitate charge transfer to or from nanostructures
ATE468314T1 (de) Verfahren zur herstellung von ameisensäure
ATE340174T1 (de) Verfahren zur umwandlung von dihidroisoxazol derivate in gamma-hydroxaminsäurederivate, z.b monatins
DE60321625D1 (de) Verfahren zur Herstellung von Acrylsäure
DE602004001816D1 (de) Verfahren zur Herstellung von Schmiedestücken bei Präzisions-Schmieden
ATE457974T1 (de) Verfahren zur herstellung von phenylmalonsäure- dinitrilen
ATE458044T1 (de) Verfahren zur nukleinsäureamplifikation
DE60321626D1 (de) Verfahren zur Herstellung von Acrylsäure
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE50302740D1 (de) Verfahren zur herstellung von verküpbaren organischen pigmenten
ATE336464T1 (de) Verfahren zur aufreinigung von blausäure
DE60331043D1 (de) Verfahren zur entfernung von dithiogruppen aus polymerkettenenden
WO2007044066A3 (en) Methods for normalizing and for identifying small nucleic acids
ATE290076T1 (de) Ein verfahren zur trennung und reinigung von rna
DE60200012D1 (de) Verfahren zur Herstellung von Luftreifen
DE60315741D1 (de) Verfahren zur Herstellung von Acrylsäure
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
ATE359287T1 (de) Ein verfahren zur herstellung von clopidogrel
ATE548395T1 (de) Verfahren zur herstellung von polyolefinen in suspension
DE502004011774D1 (de) Verfahren zur herstellung von leder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties